Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:807

Official publication of the Indian Society of Nephrology
 ~ Next article
 ~ Previous article 
 ~ Table of Contents
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (136 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded64    
    Comments [Add]    

Recommend this journal


Previous articleNext article
Year : 2010  |  Volume : 20  |  Issue : 4  |  Page : 224-225

Authors' reply

Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh-160 012, India

Date of Web Publication1-Dec-2010

Correspondence Address:
V Sakhuja
Department of Nephrology, Postgraduate Institute of Medical Education & Research, Chandigarh-160 012
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 21206693

Rights and PermissionsRights and Permissions

How to cite this article:
Sreejith P, Jha V, Kohli H S, Rathi M, Gupta K L, Sakhuja V. Authors' reply. Indian J Nephrol 2010;20:224-5

How to cite this URL:
Sreejith P, Jha V, Kohli H S, Rathi M, Gupta K L, Sakhuja V. Authors' reply. Indian J Nephrol [serial online] 2010 [cited 2021 Jan 16];20:224-5. Available from:


We appreciate the keen interest [1] in our case report "Allograft and prostatic involvement in a renal transplant recipient with disseminated tuberculosis: a case report" [2] and very relevant issues raised. In this regard, we would like to bring to your attention that:

  1. The KDIGO clinical practice guidelines for the care of kidney transplant recipients [3] recommend susceptibility testing on all isolates of Mycobacterium tuberculosis from kidney transplant recipients because the recipients may belong to diverse geographic locations where the prevalence of drug resistance may vary. Identifying drug susceptibility is all the more important in transplant recipients in view of the limited drug options available for them due to significant interaction of rifamycins with calcinurin inhibitors (CNIs) and mTOR inhibitors.The current recommendation for treatment of tuberculosis in kidney transplant recipient is to use the same treatment regimen as used in local general population who require therapy. [3] Rifampicin may be substituted with rifabutin with close monitoring of CNI drug levels, or a fluoroquinolone may be used instead of rifamycins. The efficacy of rifamycin sparing regimen in kidney transplant recipients has been reported from our center in the past. [4],[5] The duration of therapy has not been defined, but it may be prudent to consider the experience from rifampicin-free regimen used in general population, which in general are 9 months or more in duration.
  2. Aguado et al. [6] has reported that treatment duration less than 9 months was associated with greater mortality, and Park et al. [7] reported that the only factor that was significantly associated with greater recurrence of TB was duration of treatment: no recurrence was observed in patients who received more than 12 months treatment, irrespective of whether the treatment regimen included rifampicin. The Spanish Society of Infectious Disease and Clinical Microbiology recommends [8] duration of at least 12-18 months in solid organ transplant recipients.
  3. The prostatic abscess in our patient was asymptomatic and was picked up only on imaging; he had no evidence of bladder outlet obstruction. Hence, an intervention for draining the same was not considered necessary. A repeat CT scan after 3 months of antitubercular chemotherapy showed complete resolution of the abscess.

  References Top

1.Kalita P, Phukan C, Ali S. Tuberculosis in renal transplant recipient. Indian J Nephrol in press.  Back to cited text no. 1
2.Sreejith P, Jha V, Kohli HS, Rathi M, Gupta KL, Sakhuja V. Allograft and prostatic involvement in a renal transplant recipient with disseminated tuberculosis. Indian J Nephrol 2010;20:40-2.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.Kidney Disease: Improving Global Outcomes (KDIGO) Transplant work group. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant 2009;9:8.  Back to cited text no. 3
4.Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996;61:211-5.  Back to cited text no. 4
5.Jha V, Sakhuja V, Gupta D, Krishna VS, Chakrabarti A, Joshi K, et al. Successful management of pulmonary tuberculosis in renal allograft recipients in a single center. Kidney Int 1999;56:1944-50.  Back to cited text no. 5
6.Aguado JM, Herrero JA, Gavaldα J, Torre-Cisneros J, Blanes M, Rufν G, Moreno A, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation 1997;63:1278-86.  Back to cited text no. 6
7.Park YS, Choi JY, Cho CH, Chang KH, Song YG, Kim YS, et al. Clinical outcomes of tuberculosis in renal transplant recipients. Yonsei Med J 2004;45:865-72.  Back to cited text no. 7
8.Aguado JM, Torre-Cisneros J, Fortϊn J, Benito N, Meije Y, Doblas A, et al. Tuberculosis in Solid-Organ Transplant Recipients: Consensus Statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009;48:1276-84.  Back to cited text no. 8


Print this article  Email this article
Previous articleNext article


Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07